Nasus Pharma will present at the H.C. Wainwright conference, focusing on its intranasal therapies including NS002 for allergic reactions.
Quiver AI Summary
Nasus Pharma Ltd., a clinical-stage pharmaceutical company specializing in innovative intranasal products, has announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference in New York from September 14-16, 2026. The company's management, including CEO Brendan O'Grady and CFO Eyal Rubin, will present at the conference, with their presentation available on demand starting September 11, 2026. The executives will also be available for one-on-one meetings with investors. Nasus Pharma is advancing intranasal therapies through its proprietary technology platform, with its lead product candidate, NS002, targeting Type I allergic reactions, including anaphylaxis. The company aims to unlock the commercial potential of its products and is progressing toward pivotal trials for NS002, with data expected in early 2027.
Potential Positives
- Nasus Pharma's participation in the H.C. Wainwright 28th Annual Global Investment Conference enhances visibility and provides an opportunity to attract potential investors.
- The presentation of the company's innovative intranasal therapies, particularly the lead product candidate NS002 for Type I allergic reactions, highlights the company's commitment to addressing significant unmet medical needs in the market.
- One-on-one meetings with investors during the conference can facilitate strong investor relations and potentially lead to funding opportunities that support the company’s growth and development initiatives.
Potential Negatives
- The press release heavily relies on forward-looking statements, which could indicate uncertainty about the company's future performance and plans.
- There is a lack of concrete updates regarding the progress of their lead product candidate, NS002, beyond its anticipated pivotal trial in the fourth quarter of 2026.
- The Company does not provide any recent financial results or metrics, which could raise concerns for investors seeking current performance indicators.
FAQ
What is Nasus Pharma's main focus?
Nasus Pharma focuses on developing innovative intranasal products and therapies, particularly for severe allergic reactions.
When will the H.C. Wainwright conference take place?
The H.C. Wainwright 28th Annual Global Investment Conference is scheduled for September 14-16, 2026.
Who will represent Nasus Pharma at the conference?
Brendan O’Grady, CEO, and Eyal Rubin, CFO, will represent Nasus Pharma at the conference.
How can investors arrange meetings during the conference?
Investors can register for the conference or contact their H.C. Wainwright representative to arrange meetings.
What is NS002 and its significance?
NS002 is Nasus Pharma's lead product candidate, designed as an intranasal epinephrine treatment for anaphylaxis and allergic reactions.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NSRX Insider Trading Activity
$NSRX insiders have traded $NSRX stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $NSRX stock by insiders over the last 6 months:
- DAN BENJAMIN TELEMAN (Chief Executive Officer) has made 3 purchases buying 24,450 shares for an estimated $61,809 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$NSRX Hedge Fund Activity
We have seen 4 institutional investors add shares of $NSRX stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HRT FINANCIAL LP removed 38,897 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $136,139
- XTX TOPCO LTD added 16,640 shares (+inf%) to their portfolio in Q2 2026, for an estimated $58,240
- CABLE CAR CAPITAL, LP added 14,083 shares (+2.3%) to their portfolio in Q2 2026, for an estimated $49,290
- RENAISSANCE TECHNOLOGIES LLC added 12,200 shares (+inf%) to their portfolio in Q2 2026, for an estimated $42,700
- UBS GROUP AG removed 3,094 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $10,829
- MORGAN STANLEY removed 1,000 shares (-50.0%) from their portfolio in Q2 2026, for an estimated $3,500
- CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD added 4 shares (+inf%) to their portfolio in Q2 2026, for an estimated $14
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
TEL AVIV, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the Company’s management team will participate and present in the H.C. Wainwright 28th Annual Global Investment Conference , to be held September 14-16, 2026 in New York, NY, at the Lotte New York Palace hotel.
The Company’s presentation will be available on demand from the conference website beginning Friday, September 11, 2026. Brendan O’Grady, Chief Executive Officer, and Eyal Rubin, Chief Financial Officer, will be available for one-on-one meetings with investors throughout the conference. Investors interested in arranging a meeting can register for the conference here or should contact their H.C. Wainwright representative.
About Nasus Pharma
Nasus Pharma Ltd. (NYSE: NSRX) is a biopharmaceutical company advancing innovative intranasal therapies through its proprietary intranasal powder technology platform. The Company's lead product candidate, NS002, is being developed as an intranasal epinephrine treatment for Type I allergic reactions, including anaphylaxis. In addition to NS002, Nasus is leveraging its proprietary technology platform to develop a growing pipeline of differentiated intranasal product candidates designed to provide rapid, reliable and patient-friendly drug delivery across multiple therapeutic areas.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. Words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will”, “would,” or the negative of these words, similar expressions or variations of such words are intended to identify forward-looking statements. For example, Nasus Pharma is using forward-looking statements in this press release when it discusses: statements regarding the Company's strategy to commercialize NS002 and unlocking its commercial potential; advancing the Company’s pipeline and future business development initiatives, maximizing the value of its proprietary Nasax intranasal technology platform; the next phase of Nasus Pharma’s growth; the Company advancing NS002 toward a pivotal trial in the fourth quarter of 2026 and topline data readout the first quarter of 2027; the increasing strategic focus on pre-commercial planning; the opportunity NS002 presents to address a significant unmet medical need; the believe that the Nasus portfolio represents a significant value generation opportunity; and the potential applications and promise of the Company’s proprietary intranasal technology platform. These forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to update or revise these forward-looking statements except as required by applicable law.
Company Contact
Nasus Pharma Ltd.
[email protected]
Investor Contact
Mike Moyer
LifeSci Advisors
+1-617-308-4306
[email protected]
